Clovis Oncology (CLVS) Posts Q2 Loss of 61c/Share, Narrower than Views

Clovis Oncology (NASDAQ: CLVS) reported Q2 EPS of ($0.61), $0.09 better than the analyst estimate of ($0.70).

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Cisco rating cut at HSBC as analyst sees a lack of catalysts
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat